MyFinsight
Home
Blog
About
Net increase
(decrease) in cash, cash...
-$20,833K
(-211.65%↓ Y/Y)
Stock-based compensation
expense
$2,550K
(-53.00%↓ Y/Y)
Accrued expenses and
other liabilities
$1,061K
(373.45%↑ Y/Y)
Operating lease
liabilities
$1,005K
(121.69%↑ Y/Y)
Prepaid expenses and
other current assets
-$719K
(63.85%↑ Y/Y)
Noncash lease expense
$541K
(-81.77%↓ Y/Y)
Depreciation and
amortization expense
$230K
(-86.29%↓ Y/Y)
Proceeds from maturities
of marketable...
$34,166K
(-78.18%↓ Y/Y)
Proceeds from issuance of
common stock upon...
$9K
(-97.71%↓ Y/Y)
Net cash used in
operating activities
-$17,844K
(60.32%↑ Y/Y)
Net cash provided by
(used in) investing...
-$2,967K
(-104.69%↓ Y/Y)
Net cash provided by
financing activities
-$22K
(-105.60%↓ Y/Y)
Canceled cashflow
$6,106K
Canceled cashflow
$34,166K
Canceled cashflow
$9K
Deferred revenue
-$16,072K
(-18.97%↓ Y/Y)
Net loss
-$7,191K
Purchases of marketable
securities
$37,083K
(-60.24%↓ Y/Y)
Payments of public
offering costs
$31K
Accretion of discount on
marketable securities
$618K
(-51.11%↓ Y/Y)
Accounts payable
-$69K
(85.10%↑ Y/Y)
Purchases of property and
equipment
$50K
(0.00%↑ Y/Y)
Back
Back
Cash Flow
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)
source: myfinsight.com